Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood

被引:28
作者
Mannello, Ferdinando [1 ]
Jung, Klaus [2 ,3 ]
Tonti, Gaetana A. [1 ]
Canestrari, Franco [1 ]
机构
[1] Univ Carlo Bo, Dipartimento Sci Biomol, Sez Biochim Clin, I-61029 Urbino, PU, Italy
[2] Humboldt Univ, Univ Hosp Charite, Dept Urol, Div Res, Berlin, Germany
[3] Berlin Inst Urol Res, Berlin, Germany
关键词
Matrix metalloproteinases; Tissue inhibitors of metalloproteinases; Peripheral blood; Serum; Plasma; Heparin; Preanalytical pitfalls;
D O I
10.1016/j.clinbiochem.2008.09.104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Blood sampling/handling alters matrix metalloproteinases (MMP) and tissue inhibitor (TIMP) expression. The aim of this study is to evaluate the effects of high molecular weight heparin on MIMP and TIMP expression in blood. Design and methods: We analyzed by gelatin zymography and ELISA assays the effects of different heparin salts, dose- and time-dependence of MMP and TIMP concentrations in plasma and sera collected with and without clot-accelerator in plastic tubes From 50 healthy donors. Results: The levels and zymography of MMP-2 did not show significant changes among all samples, and during time- and dose-dependent heparin treatments. MMP-9 and TIMP-2 expression were strongly affected by heparin, with significant increase of their content and gelatinolytic activity both in time- and in dose-dependent fashion. Addition of heparin allowed also the displacement of MMP-2 prodomain, favoring zymogen activation. Conclusions: Heparin has direct and indirect effects, altering MMP/TIMP complexes circulating in blood, and increasing the release of TIMP-2. To avoid misinterpretations due to MMP/TIMP complex alteration and MMP prodomain displacement, heparin should be cautiously used in blood collection procedures. (c) 2008 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1466 / 1473
页数:8
相关论文
共 46 条
[1]   Effects of anticoagulants on the activity of gelatinases [J].
Castellazzi, Massimiliano ;
Tamborino, Carmine ;
Fainardi, Enrico ;
Manfrinato, Maria C. ;
Granieri, Enrico ;
Dallocchio, Franco ;
Bellini, Tiziana .
CLINICAL BIOCHEMISTRY, 2007, 40 (16-17) :1272-1276
[2]   Differential regulation of platelet aggregation by matrix metalloproteinases-9 and-2 [J].
Fernandez-Patron, C ;
Martinez-Cuesta, MA ;
Salas, E ;
Sawicki, G ;
Wozniak, M ;
Radomski, MW ;
Davidge, ST .
THROMBOSIS AND HAEMOSTASIS, 1999, 82 (06) :1730-1735
[3]   RETRACTED: Activation and silencing of matrix metalloproteinases (Retracted article. See vol. 20, pg. 375, 2009) [J].
Fu, Xiaoyun ;
Parks, William C. ;
Heinecke, Jay W. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2008, 19 (01) :2-13
[4]   Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma [J].
Gerlach, Raquel F. ;
Demacq, Caroline ;
Jung, Klaus ;
Tanus-Santos, Jose E. .
CLINICAL BIOCHEMISTRY, 2007, 40 (1-2) :119-123
[5]   Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities [J].
Gerlach, RF ;
Uzuelli, JA ;
Souza-Tarla, CD ;
Tanus-Santos, JE .
ANALYTICAL BIOCHEMISTRY, 2005, 344 (01) :147-149
[6]  
JOHANSSON S, 1986, J BIOL CHEM, V261, P4363
[7]   Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases [J].
Jung, K .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (04) :500-502
[8]   Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes [J].
Jung, K ;
Meisser, A ;
Bischof, P .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (06) :1000-1001
[9]  
Jung K, 1998, CLIN CHEM, V44, P1060
[10]   Circulating gelatinase B (MMP-9) - the impact of the preanalytical step of blood collection [J].
Jung, K ;
Lein, M ;
Roemer, A ;
Lichtinghagen, R .
MATRIX BIOLOGY, 2002, 21 (05) :381-382